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Chapter
Sepsis Associated Acute Kidney 
Injury
Titik Setyawati, Ricky Aditya and Tinni Trihartini Maskoen
Abstract
AKI is a syndrome consisting of several clinical conditions, due to sudden 
kidney dysfunction. Sepsis and septic shock are the causes of AKI and are known 
as Sepsis-Associated AKI (SA-AKI) and accounted for more than 50% of cases of 
AKI in the ICU, with poor prognosis. Acute Kidney Injury (AKI) is characterized 
by a sudden decline in kidney function for several hours/day, which results in the 
accumulation of creatinine, urea and other waste products. The most recent defini-
tion was formulated in the Kidney Disease consensus: Improving Global Outcome 
(KDIGO), published in 2012, where the AKI was established if the patient’s cur-
rent clinical manifestation met several criteria: an increase in serum creatinine 
levels ≥0.3 mg/dL (26.5 μmol/L) within 48 hours, an increase in serum creatinine 
for at least 1.5 times the baseline value within the previous 7 days; or urine vol-
ume ≤ 0.5 ml/kg body weight for 6 hours. The AKI pathophysiology includes 
ischemic vasodilation, endothelial leakage, necrosis in nephrons and microtrombus 
in capillaries. The management of sepsis associated with AKI consisted of fluid 
therapy, vasopressors, antibiotics and nephrotoxic substances, Renal Replacement 
Therapy (RRT) and diuretics. In the analysis of the BEST Kidney trial subgroup, the 
likelihood of hospital death was 50% higher in AKI sepsis compared to non-sepsis 
AKI. Understanding of sepsis and endotoxins that can cause SA-AKI is not yet fully 
known. Some evidence suggests that renal microcirculation hypoperfusion, lack of 
energy for cells, mitochondrial dysfunction, endothelial injury and cycle cell arrest 
can cause SA-AKI. Rapid identification of SA-AKI events, antibiotics and appropri-
ate fluid therapy are crucial in the management of SA-AKI.
Keywords: Sepsis, Acute kidney injury
1. Introduction
Acute Kidney Injury is a syndrome that consists of several clinical conditions, 
due to sudden kidney dysfunction (within a few hours to several days) that causes 
retention of residual nitrogen (urea-creatinine) and non-nitrogenous metabolism, 
with or without oligouria, and is affected by some underlying disease. The most 
common causes of AKI in patients with critical illness are sepsis and septic shock, 
accounting for more than 50% of AKI cases in the ICU. The incidence of sepsis and 
AKI in critical patients increases gradually and both shows poor prognosis. In vari-
ous epidemiological studies, it is said that AKI occurs in 11-60% of sepsis patients, 
23% of severe sepsis patients and 51 – 64% in septic shock patients [1, 2]. Sepsis is 
one of the causes of Acute Kidney Injury (AKI) in critically ill patients treated in 
the ICU known as Sepsis-Associated AKI (SA-AKI). The morbidity and mortality 
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rate of SA-AKI is still quite high even though the development of supportive care 
technology has progressed. A good understanding of SA-AKI is expected to increase 
alertness and make appropriate decisions in initiating management so as to provide 
better outcomes for patients with SA-AKI in the ICU.
By definition, Sepsis is a life-threatening condition of organ dysfunction due to 
an uncontrolled body’s response to a systemic infection. Meanwhile, septic shock 
is part of sepsis with higher mortality characterized by hypotension requiring 
vasoactive therapy to maintain an average arterial pressure of at least 65 mmHg and 
serum lactate above 2 mmol/L despite adequate fluid resuscitation with a mortality 
rate of>40% [2]. Organ dysfunction caused by inflammatory response can be used 
to distinguish infections with sepsis, using Sequential Organ Failure Assessment 
(SOFA) scoring where a minimum of 2 points is the most recent associated with 
a mortality rate of 10% [3–5]. Critically ill patients with sepsis when patients are 
undergoing treatment in the Intensive Care Unit (ICU) may experience organ fail-
ure, especially in the respiratory system (43%) and the renal system (36%) [6, 7].
2. Literature review
2.1 Definition
According to the latest definition, sepsis is characterized by suspicion or evi-
dence of infection plus clinical signs and laboratory findings that indicate organ 
dysfunction (based on the SOFA/Sequential Organ Failure Assessment score) due 
to an immune response to the infection. The heart, liver, lungs and kidneys are 
organs that are often affected during this process [2]. For a longtime sepsis has been 
known as a cause of morbidity and mortality; the consensually agreed upon defini-
tion of sepsis has only been around for the last few decades [3]. The first consensual 
definition defined sepsis as a continuous physiological and serological disorder that 
causes progressive organ failure.
The consensual definition of Sepsis-3 is the response to the limitations of the old 
definition, where SIRS and severe sepsis are removed. Sepsis is defined as life-threat-
ening organ dysfunction due to the body’s uncontrolled response to infection. Organ 
dysfunction can be identified by a condition of acute changes associated with infec-
tion with at least 2 points on a Sequential Organ Failure Assessment (SOFA score), 
increasing the mortality rate by 10% [2]. The determination of the sepsis diagnosis in 
patients with infection can use the quick SOFA score, where two of the three criteria 
can meet the criteria of sepsis. Meanwhile, septic shock is sepsis with hypotension 
that requires a vasopressor to maintain a minimum MAP of 65 mmHg and serum 
lactate above 2 mmol/L despite adequate fluid resuscitation; this condition has a 
mortality rate of 40% [4]. Based on the European Society of Intensive Care Medicine 
and the Society of Critical Care Medicine’s Third International Consensus Definition 
for Sepsis and Septic Shock in 2016, sepsis is defined as life-threatening organ dys-
function caused by dysregulation of the body’s response to infection. So, the criteria 
for sepsis must also include the three elements, namely, infection, body response and 
organ dysfunction. The criterion for the diagnosis of sepsis is established through a 
SOFA (Sequential/Sepsis-related Organ Failure Assessment) score ≥ 2 [5].
Given the significantly high mortality rates, AKI as one of the most frequent 
complications of sepsis is considered an important issue in clinical practice and 
especially for hospitalized patients treated in the ICU. This may be due to the lim-
ited understanding of the pathogenesis of SA-AKI sepsis, the lack of ability to assess 
kidney function in early diagnosis of AKI, and the absence of specific treatments 
other than supportive care [3].
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AKI is characterized by a sudden decline in kidney function for several hours to 
days, resulting in the accumulation of creatinine, urea and other waste products. 
The latest definition was formulated in the consensus of Kidney Disease: Improving 
Global Outcome (KDIGO) in 2012, where the AKI was established if it met the 
criteria: an increase in serum creatinine levels ≥0.3 mg/dL (26.5 μmol/L) within 
48 hours, an increase in serum creatinine at least 1.5 times the baseline value within 
the previous 7 days, or urine volume ≤ 0.5 ml/kg body weight for 6 hours [6].
The initial definition of AKI was the result of the international consensus of 
the Acute Dialysis Quality Initiative (ADQI) in 2004 that produced RIFLE (Risk, 
Injury, Failure, Loss, End stage Kidney disease) criteria based on an assessment 
of increased serum creatinine, decreased Glumerular Filtration Rate (GFR) urine 
production, loss if AKI lasts >4 weeks and end stage Kidney disease if AKI con-
tinues >3 months [7]. Then in 2007, the Acute Kidney Injury Network (AKIN), an 
international nephrological network or community in the USA and Europe, issued 
a more specific measure on RIFLE criteria focusing on the condition of the injury, 
i.e. Risk, Injury, and Failure were changed into stages (stage 1, stage 2, stage 3); Loss 
and end stage Kidney disease was eliminated; and an increase in serum creatinine of 
0.3 mg/dL within 48 hours was added [8].
In 2012, the KDIGO issued clinical guidelines for the management of AKI 
and made a classification of AKI by combining RIFLE and AKIN criteria. This 
KDIGO-based classification defines AKI based on an increase in serum creatinine 
of 0.3 mg/dL within 48 hours or an increase of 1.5 x serum creatinine from baseline 
or urine production <0.5 ml/kg/hour for 6-12 hours. Baseline serum creatinine 
is the examination value obtained in the last 7 days. KDIGO also introduced the 
definition of Acute Kidney Disease (AKD), where an increase in serum creatinine 
>7 days and < 3 months. This condition occurs due to injury to the kidney and it can 
also occur slowly, different from AKI with a significant decrease in kidney function 
occurring within 7 days after the cause of injury to the kidney [9].
In patients who meet both the criteria for sepsis and AKI, it is called SA-AKI [10, 
11]. Sepsis can be associated with >50% of AKI cases, and > 60% of sepsis patients 
can experience AKI. SA-AKI can also be interpreted as AKI which is caused or 
worsened by sepsis, so that it can be classified as a different condition in AKI which 
is usually caused by nephrotoxic regimens and ischemic conditions. The inflamma-
tory response is more prominent in SA-AKI compared to nephrotoxic and ischemic 
AKI [12, 13]. SA-AKI is a clinical syndrome due to acute damage to organ function 
and damage. It is related to long-term adverse outcomes depending on the severity 
of the underlying organ damage. In general, SA-AKI should be considered a syn-
drome, characterized by fulfilling the criteria for sepsis and AKI [6].
2.2 Epidemiology
Acute Kidney Injury (AKI) is a syndrome with a broad spectrum of etiology and 
various mechanisms; ischemia/hypoxia, nephrotoxics and inflammation play a role 
in the development of AKI. Among the various etiologies of AKI, sepsis is one of 
the main causes of AKI in the ICU. According to various reported data, 45-70% of 
all AKI cases are related to sepsis [8]. Among ICU patients in general, the incidence 
of AKI varies from 6–67% depending on the study population. The incidence of 
SA-AKI in patients treated in ICU varies from 13–78% depending on the severity of 
sepsis and the AKI criteria used. In patients with critical illness with AKI, as many 
as 20-67% also suffer from sepsis, severe sepsis or sepsis shock. Research conducted 
by Angus and others on 192,980 patients with severe sepsis from seven states in 
the United States found that AKI occurred in 22% of sepsis patients with a mortal-
ity rate of 38.2%. Whereas in the cohort study conducted by The Sepsis Occuring 
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in Acutely Ill Patients (SOAP) on 3,147 patients treated in 198 ICUs throughout 
Europe, 37% of patients had sepsis and AKI occurred in 51% of them with a mortal-
ity rate in ICU of 41%. The FINNAKI study of 2,901 critically ill patients treated 
in ICU in Finland found that among 918 patients with severe sepsis, 53% met the 
KDIGO criteria for AKI [6].
SA-AKI is associated with a higher risk of death and mortality in hospitals. If 
the MMR has an overall mortality rate of 45%, the mortality rate of SA-AKI is much 
higher, which is above 70%. Bagshaw and others in their study found that mortality 
rates from SA-AKI cases in hospitals and intensive care units/ICUs had increased by 
30% and 20% respectively, but it was also suggested that the severity of AKI had a 
positive correlation with morbidity and mortality rates of ICU patients, the higher 
the severity of AKI, the higher the mortality rate. Population at high risk for SA-AKI 
are elderly patients, females, and those with the presence of comorbidities such as 
diabetes mellitus, chronic kidney failure, congestive heart failure and malignancy. 
Sources of infection and side effects from treatment also contribute to risk factors 
for SA-AKI such as intra-abdominal infections, urosepsis, endocarditis and blood-
stream infections [14, 15].
2.3 Etiology
Acute Kidney Injury (AKI) is a syndrome with a broad spectrum of etiology. 
Based on the mechanism of the cause, AKI can be divided into pre-renal, renal, and 
post-renal AKI.
1. The cause of pre-renal AKI is renal hypoperfusion, due to hypovolemia or a 
decrease in effective circulation volume, such as in the case of sepsis and heart 
failure, and intrarenal haemodynamic disorders, such as the use of non-steroi-
dal anti-inflammatory drugs.
2. Renal AKI is caused by abnormalities in the vascular or tubular components of 
the kidney directly, such as vasculitis, malignant hypertension, acute glo-
merular nephritis, interstitial nephritis, nephrotoxic substances, etc., causing 
intrarenal vasoconstriction, ischemia and decreased renal filtration rate.
3. Post renal AKI is usually caused by intrarenal and extra renal obstruction 
problems that interfere with kidney blood flow [14].
2.4 Pathophysiology
The pathophysiology of the SA-AKI is not yet fully known, and so far it has only 
been known from the results of studies on animal models that may be of relevance 
only to specific conditions in humans. From studies in animals and humans, 
SA-AKI occurs due to an excessive inflammatory response that causes injury to the 
kidneys, injury to the tubular tight junction, cell cycle arrest, cellular apoptosis and 
others [4].
The immune response to sepsis will cause microcirculation dysfunction (in 
tubular and glomerular capillaries) due to the proinflammatory response resulting 
in injury to endothelial cells. Vascular permiability will increase and there will be 
a decrease in endothelial Nitric Oxide Synthase (eNOS) activity, which functions 
to inhibit platelet aggregation and leukocyte activation. Meanwhile, induction of 
Nitric Oxyde Synthase (iNOS), which works otherwise, will increase its activity. 
This condition will cause ischemia and hypoxia. Inflammatory reactions will also 
cause a cycle cell arrest and apoptosis as a form of protection so that the damage is 
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not widespread. As a result of ischemic and hypoxia, cells will lack energy so that 
the mitochondria work abnormally, causing injury to the mitochondria, so that 
injury to the kidneys continues and kidney function will be disrupted.
In sepsis the pathophysiological process of AKI can be caused by the following 
process:
1. Ischemic vasodilation, causing a decrease in Renal Blood Flow (pre renal AKI) 
due to an increase in Nitrides Oxyde induced by iNOS.
2. Endothelial leakage, causing edema and increased renal interstitial hydrostatic 
pressure (glomerulus and tubules), thereby reducing kidney filtration.
3. Nephrosis of the nephron due to the release of neutralizing agents triggered 
by the release of mediators in sepsis (the formation of ROS or the ischemic 
process itself causes necrosis of the nephron).
4. Capillary microtrombus due to coagulopathy and platelet leukocyte activation 
in the kidney endothelium.
2.4.1 Early detection of SA-AKI
Sepsis and AKI can each increase morbidity and mortality, length of stay, and 
treatment costs, so early detection of SA-AKI is very important to be able to inter-
vene earlier and provide better outcomes for patients. Especially for AKI, given the 
definition and classification generated from the consensus, it can actually be easier 
to diagnose AKI by the method of assessing the increase in serum creatinine and 
urine production. However, this method has limitations, where changes in serum 
creatinine run slowly and assessment of urine production is usually only routinely 
done in the ICU. Therefore, several bio-markers have begun to be investigated to 
be able to detect SA-AKI earlier. Biomarkers can be categorized into two groups: 1. 
Assessment of renal function, 2. Detection of injury to kidney cells. Biomarkers for 
detecting SA-AKI include: Cystatin C (Cys-C), Neutrophil Gelatinase-Associated 
Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18), 
Liver Type Fatty Acid -Binding (L-FABP), soluble-triggering receptor Expressed on 
Myeloid cells-1 (sTREM-1) and Activating Transcriptional Factor-3 (ATF-3). The 
sensitivity and specificity of the biomarkers varies depending on the time of mea-
surement and the type of sample used. In general, biomarkers from blood (serum) 
are lower in sensitivity compared to biomarkers from urine samples [16, 17].
Neutrophil Gelatinase-Associated Lipocalin (NGAL) is currently the chosen 
biomarker in AKI cases, because it can be a biomarker for proximal tubular func-
tion and for kidney injury. Below (Table 1) are some biomarker studies that assess 
the time, sensitivity and specificity of several biomarkers derived from serum and 
urine to detect SA-AKI from the last few years.
2.5 Clinical description
Signs and symptoms of sepsis vary not only with regard to organ involve-
ment, but also from one individual to another because of the patient’s special 
characteristics, vulnerability, and disease. Signs of sepsis reflect the phase of the 
disease and vary from symptoms confined to the main organ (e.g pneumonia) to 
severe multi-organ dysfunction syndrome (MODS) and septic shock. Health care 
workers must be alert for signs of infection, sepsis or septic shock when evaluating 
patients for kidney failure. Conversely, it is important to frequently monitor kidney 
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function (along with other organ involvement) in patients with documented or 
suspected sepsis.
Clinical studies based on physiological data and some postmortem reports have 
recently begun to define AKI caused by sepsis and how it differs from other types 
of kidney injury. Histologically, AKI induced by sepsis is characterized by hetero-
geneous tubular cell injury with apical vacuolization, but in the absence of tubular 
necrosis or even extensive apoptosis. All of these features can develop in the context 
of normal or increased renal blood flow (Renal Blood Flow/RBF) and represent a 
clinical phenotype characterized by decreased levels of glomerular filtration (GFR), 
creatininclearance, and uremia [18].
2.6 Diagnosis
A diagnosis of AKI caused by sepsis requires a diagnosis of sepsis and subse-
quent events of AKI. This is considered a PIRO (predisposition, infection, response, 
organ dysfunction) system. The diagnosis of sepsis is more complex than the origi-
nal. In the new definition, several other important aspects of sepsis are included 
such as hemodynamics and organ dysfunction [18].
A 2016 task force organized by the national community including the Society 
of Critical Care Medicine (SCCM) and the European Society of Intensive Care 
Medicine (ESICM) proposed a new definition of sepsis, called Sepsis-3. This con-
sensus defines sepsis as life-threatening organ dysfunction caused by dysregulation 
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From the above mention, it can be shown that both NGAL and Cyst C measurements from urine have higher 
sensitivity and specificity than serum and both of them can be detected earlier than creatinine. It can be also detected 
as urine biomarkers.*NGAL: Neutrophil Gelatinase-Associated Lipocalin.
**Cys-C: Cystatine C.
Table 1. 
Research with NGAL and Cys-C biomarkers.
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of the responhost to infection. The new definition does not use the Systemic 
Inflammatory Response Syndrome’s (SIRS) criteria in the identification of sepsis 
and elimination of severe sepsis [18].
Sequential Organ Failure Assessment (SOFA) is a simple and objective score 
that allows for calculating both the number and severity of organ dysfunction in six 
organ systems (breathing, coagulation, liver, cardiovascular, kidney, and neurologi-
cal), and the score can measure individual or aggregate organ dysfunction [19].
Early detection of AKI in ICU settings is very important. AKI has become a 
major issue with the increasing number of incidents, causing more than four mil-
lion deaths per year worldwide. Also, the lack of a reliable initial biomarker for AKI 
causes a significant delay in starting an appropriate therapy. This is in contrast to 
the “biological revolution” in cardiology, which produces various markers (includ-
ing troponin) for early diagnosis of heart damage that allows for early and effective 
treatments [19].
The diagnosis of AKI is based on an increase in serum creatinine and/or a 
decrease in urine output. The definition has evolved from the criteria of Risk, 
Injury, Failure, Loss, Endstage (RIFLE) (Table 2) in 2004 to the classification of the 
Acute Kidney Injury Network (AKIN) in 2007. In 2012, the two were merged, form-
ing the Kidney Disease Improving Global Outcomes (KDIGO) classification [10].
Combined with evidence-based medicine, KDIGO published KDIGO guidelines 
in March 2012 and established diagnostic criteria for AKI (Table 3): increase in 
serum creatinine >0.3 mg/dl (26.5 μmol/L) within 48 hours; or an increase in serum 
creatinine to 1.5 times the baseline, which is known or thought to have occurred 
within 7 days; or urine output <0.5 ml/kg/hour for 6-12 hours. According to the 
severity, this condition is divided into stages 1, 2, and 3, similar to the classification 
of AKIN [10].
Categories Serum Creatinine Criteria Urine Output Criteria
RIFLE*
Risk ↑ in SCr to 1.5 – < 2 x baseline UO <0.5 mL/kg/hr. for 6 hrs
Injury ↑ in SCr to 2 – < 3 x baseline UO <0.5 mL/kg/hr. for 12 hrs
Failure ↑ in SCr to ≥3 x baseline UO <0.3 mL/kg/hr. for 24 hrs or Anuria for 
12 hrs
Loss Loss of Kidney function for >4 wks
ESRD Loss of Kidney function for >3 mos
AKIN**
Stage 1 ↑ in SCr to 0.3 mg/dL or to 1.5 – 2 x 
baseline
UO <0.5 mL/kg/hr. for >8 hrs
Stage 2 ↑ in SCr to >2 – 3 x baseline UO <0.5 mL/kg/hr. for >12 hrs
Stage 3 ↑ in SCR to >3 x baseline or UO <0.5 mL/kg/hr. for >24 hrs
Stage 4 SCr ≥ 4 mg/dL with an acute increase of 
≥0.5 mg/dL
or Anuria for 12 hrs
There are little bit differences between RIFLE and AKIN Criteria, LOSS and ESRD in RIFLE criteria are included 
in Stage 4 in AKIN criteria.*RIFLE: Risk, Injury, Failure, Loss, ESRD (End Stage Renal Disease; AKIN: Acute 
Kidney Injury Network.
**AKIN Criteria require the increase of serum creatinine to occur within 48 hrs; SCr: Serum Creatinine; UO: Urine 
Output.
Table 2. 
RIFLE and AKIN CRITERIA of AKI.
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The KDIGO guidelines highlight early diagnosis and treatment of AKI and diag-
nostic markers remain at serum creatinine levels. Because serum creatinine tests 
are convenient and inexpensive, they can be used as practical clinical indicators. 
However, there are some limitations. Renal hypoperfusion due to prerenal causes 
can cause an increase in creatinine, although there is no interference with the renal 
parenchyma. When the renal parenchyma is injured, renal compensation can cause 
lag in creatinine increase. Further, injury to 50% of the kidneys can occur without 
an increase in creatinine levels, so diagnosis and intervention are delayed. Thus, 
new markers with higher sensitivity and specificity are expected to help the initial 
diagnosis of AKI. At present, many studies report the presence of early diagnostic 
markers of AKI. Some of them are clinical trials that show good sensitivity and 
specificity, with initial diagnostic values for AKI. In addition, different biological 
markers have been shown to show various mechanisms of injury [20].
Evidently, AKI occurs through complex mechanisms often due to several factors. 
Different mechanisms cause injury in various parts of the kidney. It is difficult to 
establish a clear diagnosis and accurate localization of the injury using the same 
marker to diagnose injury to all kidney subregions caused by all diseases. Discrete 
studies of certain diseases and related kidney injuries will definitely improve 
diagnostic accuracy. About 45 – 70% of MMR is associated with sepsis, which is 
one of the most important causes of MMR. Furthermore, the proportion of septic 
patients with secondary kidney injury is 16 – 50%, whereas the mortality of sepsis 
associated with AKI is up to 50 – 60%. As such, pursuing focused studies of sepsis-
induced AKI and searching for biomarkers associated with early diagnosis will help 
in solving important clinical problems of septic patients and AKI disease [20].
2.7 Management
As with sepsis management in general, the main therapy for SA-AKI is the provi-
sion of appropriate antibiotics and good supportive care. There are several things 
that must be considered in the management of SA-AKI:
2.7.1 Fluid therapy
Giving fluids is still fundamental in the treatment of sepsis. Patients who are 
responsive after being given fluids (fluid responder) can theoretically be inter-
preted as patients who have increased the stroke volume of 10-15% after giving a 
fluid challenge of 250-500 ml; in reality, there are less than 40% of sepsis patients 
who need fluids or fluid responder. Based on the Frank-Starling principle, if 
Stage Serum Creatinine and urine output criteria
1 Serum creatinine increased 1.5 – 1.9 x baseline or increase ≥26.4 umol/L (0.3 mg/dL) or urinary 
output <0.5 ml/kg/h during a 6 hour block
2 Serum creatinine increased 2.0 – 2.9 x baseline or urinary output <0.5 ml/kg/h during two 6 
blocks
3 Serum creatinine increased >3 x baseline or increased to ≥353 Umol/L (4 mg/dL) or initiation of 
renal replacement therapy or Urinary output <0.3 ml/kg/h during more than 24 hours or anuria 
For more than 12 hours
KDIGO: the Kidney Disease Improving Global Outcomes.
KDIGO criteria is most simple than RIFLE and AKIN, there are only 3 stages of AKI, but still using creatinine 
serum and urine output criteria.
Table 3. 
KDIGO criteria of AKI.
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preload increases, the stroke volume will increase until it reaches the optimal 
preload volume. And if the preload given can no longer increase stroke volume, the 
volume of liquid given can be dangerous because it can increase arterial pressure, 
venous pressure, and ultimately pulmonary hydrostatic pressure. Further, the con-
dition will stimulate the release of natriuretic peptide causing fluid transfer from 
the intravascular space to the interstitial space. Kidney function will also be affected 
by this condition where there is a decrease in GFR due to increased venous pressure, 
potentially increasing subcapsular pressure in the kidneys due to fluid transfer.
The “Fluid Expansion as Supportive Therapy” (FEAST) research can explain 
the dangers of giving fluid loading to patients with sepsis, where aggressive fluid 
therapy is associated with increased mortality.
In 2001, the concept of “early aggressive fluid resuscitation” was issued, known 
as the Early Goal Directed Therapy (EGDT). Following this, studies began using 
the EGDT protocol. It is interesting to find the reduction in mortality by reducing 
the volume of resuscitation fluid in the first 72 hours. Although the early sepsis 
phase shows an effective condition of circulating volume reduction, making it 
possible for fluid resuscitation to take place, the subsequent fluid therapy given 
can cause problems especially in the SA-AKI [21]. Besides being unable to improve 
septic shock, fluid therapy can also contribute to causing renal dysfunction 
through several mechanisms. The most rapid occurrence is an increase in venous 
pressure due to fluid therapy that directly increases the renal interstitial pressure 
and peritubular area in animal models [22]. Because the administration of large 
fluid boluses (20-30 ml/kg) is associated with the occurrence of fluid overload, it 
is currently recommended to use fluid volumes with lower volumes (200-500 ml) 
[22]. The 2014 Acute Dialysis Quality Initiative (ADQI) recommends giving fluid 
therapy to sepsis patients divided into 4 stages, namely using the rescue protocol, 
optimization, stabilization and de-escalation. A large liquid volume of 500 ml in a 
maximum of 15 minutes only at the rescue stage is given to overcome hypotension 
with close monitoring. At the optimization stage, a 100-200 ml fluid challenge for 
5-10 minutes can be done. At the stage of stabilization, the patient is stable and fluid 
administration is a maintenance therapy of 1-2 ml/kg/hour.
The three stages above are followed by de-escalation, which is the stage to reduce 
total body fluids with the help of diuretics or Renal Replacement Therapy (RRT) with 
the target of negative cumulative fluid balance. Assessment of volume status dur-
ing fluid therapy can proceed with the Passive Leg Raising method combined with 
measurement of stroke volume in real-time. This procedure is proven to be the most 
precise in assessing volume status clinically. The availability of ultrasound equipment 
in the ICU can prevent fluid overload by assessing the B-line on the Lung Ultrasound 
and the vena cava collapsibility index to assess the fluid responder. The MAP target of 
65 – 75 mmHg is an adequate target for maintaining renal perfusion [22].
Fluid selection is also a consideration in the SA-AKI. Normal 0.9% saline is 
actually a non-physiological fluid and is less well administered to SA-AKI than 
other crystalloids. Normal saline can cause hyperchloremic metabolic acidosis, 
which can cause a decrease in Renal Blood Flow (RBF) by activating the mechanism 
of tubuloglumerular feedback and afferent vasoconstriction so as to increase the 
risk of further kidney injury. In a retrospective study involving 60734 adults with 
septic shock, normal single saline can increase mortality compared with crystalloid 
balance solution. Albumin has also been investigated for its use in sepsis patients 
with the risk of SA-AKI in the SAFE study, showing that albumin was not effective 
in reducing mortality and RRT requirements when compared with crystalloid fluids 
[23]. So that until now albumin cannot be recommended as a resuscitation fluid in 
SA-AKI. Hydroxyethyl Starches (HES) is not recommended and should not be used 
on SA-AKI.
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2.7.2 Vasopressor
Norepinephrine is still the main therapy for septic shock and has been shown to 
increase MAP and improve perfusion to the kidneys. Norepinephrine itself is the 
first choice in various clinical studies and provides better outcomes and fewer side 
effects than other vasopressors. However, due to animal studies showing that nor-
epinephrine can cause medullary hypoxia renal in SA-AKI, researchers have begun 
to look for other vasopressors in the condition of sepsis and SA-AKI. Vasopressin 
is the most desirable vasopressor to study; Vasopressin and Septic Shock (VAST) 
research tries to compare norepinephrine with vasopressin with the same results on 
the outcome and no side effects are obtained. Further, VANISH research proceeds, 
the results of which showing the absence of AKI events and side effects of both. 
Based on these data, vasopressin is the second-line choice of the current vasopressor 
and has been included in the latest sepsis guidelines. Angiotensin II is a hormone 
in the renin-angiotensin-aldosterone system which has also begun to be studied in 
shock conditions. Angiotensin II for the Treatment of High Output Shock (ATHOS) 
study in 344 patients with shock due to vasodilation (259 with sepsis) found that 
Angiotensin II significantly increased MAP. Improvements were also seen in SOFA 
cardiovascular scores. Another smaller study of patients who needed RRT showed 
that patients who received angiotensin II had a greater 28-day survival rate and 
were free of RRT on the seventh day more than placebo. If these results can be vali-
dated by larger studies, there is a possibility that angiotensin II can be a meaningful 
therapy for SA-AKI [23].
Levosimendan is a calcium sensitizing drug and has an inotropic effect that 
is often used in cord decompensation. One small study showed an increase in 
creatinine clearance and urine production compared to dobutamine. However, in a 
larger scale study comparing it with placebo (MAKE-28), there was no difference in 
outcomes in the kidney. So, there is no data to support its use in the SA-AKI [24].
2.7.3 Antibiotics and nephrotoxic substances
The survival rate in sepsis patients will decrease by 7.6% per hour if no appropri-
ate antibiotic therapy is given. Regarding AKI, vancomycin antibiotics are reported 
to cause AKI even at the recommended dosage for infections caused by methicillin-
resistance Staphylococcus aureus (MRSA) and it is also reported that vancomycin 
enhances the nephrotoxic effect of the antibiotic piperazilin-tazobactam. Then 
other nephrotoxic substances must also be avoided such as Amphotericin B, iodine 
contras substances, godalinium (a contrast agent for MRI) that can cause AKI [24].
2.7.4 Renal Replacement Therapy (RRT)
There are several aspects that must be considered in kidney replacement ther-
apy, namely indication, time, modality and dosage given. Clinical indications that 
have been known so far, which are Acidosis, Electrolyte disturbances, Intoxication, 
O-fluid Overload and Uremia (A-E-I-O-U), can be applied to SA-AKI. Severe meta-
bolic acidosis, fluid overload and uremia are the three most common indications of 
RRT in SA-AKI [24].
Criteria for Renal Replacement Therapy (hemodialysis) in critically ill patients 
with AKI include:
• Oligouria: urine output <2000 ml in 12 hours
• Anuria: urine production <50 ml in 12 hours
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• Hyperkalemia: potassium levels>6.5 mmol/L
• Severe acidemia (acid poisoning): pH <7.0




• Abnormalities of plasma sodium concentration > 155 mmol/L or < 120 mmol/L
• Hypertemia
• Drug poisoning
At the time of the RRT initiation, the available data give different answers. 
Although undesirable effects have been reported due to the late initiation of the 
RRT, leading to increased mortality and poor outcomes in the SA-AKI [25]. Up 
until this, the RRT initiation is still individual. Bouman et al. showed no signifi-
cant difference in renal outcomes in early and late hemofiltration in patients who 
were able to survive. There are two large studies, with conflicting conclusions, 
specifically designed to determine the time of initiation of RRT in the condition 
of critically ill patients. The ELAIN study comparing early versus late initiation 
of the RRT shows the benefits of early strategy in reducing mortality. While in 
the AKIKI study, the results show the opposite, i.e. early strategy gives negative 
results. In both of these studies there were differences in inclusion criteria; in 
the ELAIN study, patients were in KDIGO stage 2 with a SOFA score of 15.6-16.0 
while in the AKIKI study patients were in KDIGO stage 3 with a SOFA score of 
10.8-10.9. Perhaps because of these different inclusion criteria, the opposite 
results were obtained. But at the moment there is an ongoing study, the STARRT-
AKI study (standard vs. accelerated initiation of renal replacement therapy in 
acute kidney injury) that might reveal the best RRT initiation time. The most 
appropriate RRT modalities for SA-AKI are also still different. Some studies show 
the advantages of Continuous Renal Replacement Therapy (CRRT) compared 
to Intermittent Hemodialysis (IHD) on survival rates and time spent for the 
kidney function to improve. Although CRRT is superior to IHD based on its 
fluid removal ability, with a lack of hypotension in patients, it is more expensive 
than IHD.
The current CRRT dose is sourced from two large studies with sepsis patients but 
not specific to SA-AKI, which is 20-25 ml/kg/hour. In the condition of the SA-AKI, 
the dose given is 30–35 ml/kg/hour. Several studies have shown that increasing the 
CRRT dose does not provide benefits and improve patient survival.
2.7.5 Antimicrobials during CRRT
CRRT significantly influences the pharmacokinetics and pharmacodynamics 
of most antimicrobial agents. This is not sufficiently anticipated by the currently 
recommended dosage guidelines. Patients are significantly at risk of receiving 
lower doses (underdosing), potentially causing treatment failure and increasing 
resistance.
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2.7.6 Diuretics
The use of diuretics to induce or increase urine production in the absence of 
hypervolemia is associated with increased mortality. KDIGO does not recommend 
the use of diuretics in the prevention or treatment of AKI. Conversely, diuretics 
can be used to improve outcomes when fluid balance remains positive or in the case 
of excess fluid (volume overload). Research by Ho and Power reviewed the use of 
furosemide in AKI and found no beneficial effect in reducing mortality.
2.8 Prognosis
Compared with other AKI etiologies, SA-AKI may have specific prognostic 
implications. In most reports, this is associated with higher short-term mortality 
rates. In the analysis of the BEST Kidney trial subgroup, the likelihood of hospital 
death is 50% higher in SA-AKI compared to non-SA-AKI. Obviously, the different 
prognosis between SA-AKI and non-SA-AKI is largely influenced by the composi-
tion of the non-sepsis group and its proportion from conditions with a poor prog-
nosis (such as cardiogenic shock). In addition, the confusing role in the relationship 
between SA-AKI and mortality needs to be overcome because all studies consis-
tently report higher disease severity at onset, with patients requiring RRT more 
frequently [6].
In contrast, for patients who survive in the hospital, SA-AKI has been associ-
ated with improved kidney improvement compared to other etiologies of AKI. 
In the BEST Kidney study, there was a tendency for lower serum creatinine and 
RRT dependence (9 vs. 14%, P = 0.052). Clearly, many other factors may play a 
role in kidney recovery such as RRT modality, RRT time, and further nephrotoxic 
or ischemic inhibition. Kidney recovery is also strongly influenced by premorbid 
conditions as illustrated by a French multicentric observational study, which 
shows that diabetic patients with SA-AKI who have survived going to the hospital 
tend to need more long-term RRT and have higher serum creatinine levels. Apart 
from short-term recovery, however, it is now clear that even one episode of AKI 
is associated with a greater risk of subsequent CKD and even end-stage renal 
disease [4].
3. Conclusion
SA-AKI is a clinical syndrome due to acute damage to function and organ 
damage associated with long-term adverse outcomes depending on the severity 
of the underlying organ damage. Generally clinical manifestations of AKI are 
more dominated by factors of precipitation or its main disease. The main purpose 
of managing AKI is to prevent further kidney damage and keep the patient alive 
until his kidney physiology returns to normal function. SA-AKI is a condition 
that is often faced by patients with sepsis in the ICU. Understanding of sepsis and 
endotoxins that can cause SA-AKI is not yet fully known. Some evidence suggests 
that renal microcirculation hypoperfusion, lack of energy for cells, mitochondrial 
dysfunction, endothelial injury and cycle cell arrest can cause SA-AKI. Rapid 
identification of SA-AKI events, antibiotics and appropriate fluid therapy are 
crucial actions in the management of SA-AKI. The availability of modality for 
organ support such as CRRT in ICU care can help patients with sepsis, due to 
kidney failure that often occurs, survive. Further studies related to SA-AKI are 
still continuing and are expected to be the basis for making a clinical guide in the 
management of SA-AKI.
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